Funding for this research was provided by:
FIS/Fondos FEDER (PI18/01366, PI19/00588, PI19/00815, DTS18/00032)
ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064, PERSTIGAN AC18/00071)
ISCIII-RETIC REDinREN (RD016/0009)
Comunidad de Madrid (B2017/BMD-3686)
Article History
Accepted: 21 November 2021
First Online: 21 December 2021
Declarations
:
: Research by the authors was supported by FIS/Fondos FEDER (PI18/01366, PI19/00588, PI19/00815, DTS18/00032, ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009), Sociedad Española de Nefrología, Fundación Renal Iñigo Álvarez de Toledo (FRIAT), and Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM.
: Jorge Rojas-Rivera has received consultancy or speaker fees from GlaxoSmithKline, Alexion Pharma Spain S.L., and Otsuka Pharmaceuticals. Alberto Ortiz has received consultancy or speaker fees or travel support from Astellas, AstraZeneca, Amicus, Amgen, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Otsuka, and Vifor Fresenius Medical Care Renal Pharma and is a Director of the Catedra Mundipharma-UAM of Diabetic Kidney Disease and the Catedra AstraZeneca-UAM of Chronic Kidney Disease and Electrolytes. F.C. Fervenza reports having consultancy agreements with Alexion Pharmaceuticals, Alnylam, and ByoCrystal; receiving research funding from Chemocentryx, Genentech Inc., Janssen Pharmaceutical, and Questcor/Mallinckrodt; being a scientific advisor for, or member of, Kidney International, Nephrology, Nephrology Dialysis Transplantation, and UpToDate; and receiving honoraria from UpToDate.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All analysis and graphics for this review were realized with MS Excel for Windows and Stata version 15.0 for Windows.
: Jorge Rojas-Rivera: conception of the study, literature search, data analysis, elaboration of tables and figures, drafting, critical review, and approval of the final manuscript. Alberto Ortiz: rafting, modifications and corrections, elaboration of tables and figures, critical review, and approval of the final manuscript. Fernando C. Fervenza: drafting, modifications, and corrections, critical review, and final approval of the final manuscript.